Article in Allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
31 authors at 20 institutions in 12 countries.
Christoph BergmannDepartment of Otorhinolaryngology, RKM740 Interdisciplinary Clinics, Düsseldorf, Germany.ORCID 0000-0002-2076-8813
Aurélie PoliNeuro-Immunology Group, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg.ORCID 0000-0002-7986-0761
Ioana AgacheFaculty of Medicine, Transylania University Brasov, Brasov, Romania.ORCID 0000-0001-7994-364X
Rodolfo BianchiniComparative Medicine, The Interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University of Vienna, University of Vienna, Vienna, Austria.ORCID 0000-0003-0351-6937
Heather J BaxSt. John's Institute of Dermatology, School of Basic & Medical Biosciences, Guy's Hospital, King's College London, London, United Kindgom.ORCID 0000-0003-0432-4160
Mariana CastellsDivision of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0001-6451-0163
Silvia CrescioliSt. John's Institute of Dermatology, School of Basic & Medical Biosciences, Guy's Hospital, King's College London, London, United Kindgom.ORCID 0000-0002-1909-5957
David DombrowiczUniversity of Lille, Inserm, CHU Lille, Institut Pasteur de Lille U1011-EGID, Lille, France.ORCID 0000-0002-0485-8923
Denisa FerastraoaruDepartment of Internal Medicine/Allergy and Immunology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.ORCID 0000-0002-9799-4800
Edda FiebigerDivision of Gastroenterology, Hepatology and Nutrition Research, Department of Medicine Research, Children's University Hospital Boston, Boston, Massachusetts, USA.ORCID 0000-0003-3385-0100
Hannah J GouldRandall Centre for Cell and Molecular Biophysics, School of Basic & Medical Biosciences, King's College London, New Hunt's House, London, United Kingdom.ORCID 0000-0003-0411-688X
Karin HartmannDepartment of Dermatology, University of Basel, Basel, Switzerland.ORCID 0000-0002-4595-8226
Elena IzquierdoIMMA, School of Medicine, Institute of Applied Molecular Medicine, CEU San Pablo University, Madrid, Spain.ORCID 0000-0002-3355-2798
Galateja JordakievaDepartment of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-5884-8256
Debra H JosephsSt. John's Institute of Dermatology, School of Basic & Medical Biosciences, Guy's Hospital, King's College London, London, United Kindgom.ORCID 0000-0002-5610-9123
Marek JutelDepartment of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.ORCID 0000-0003-1555-9379
Francesca Levi-SchafferPharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, The Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel.ORCID 0000-0003-0620-2810
Leticia de Las VecillasDepartment of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain.ORCID 0000-0003-4969-5678
Michael T LotzeG.27A Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.ORCID 0000-0003-3988-5419
Gabriel OsbornSt. John's Institute of Dermatology, School of Basic & Medical Biosciences, Guy's Hospital, King's College London, London, United Kindgom.ORCID 0000-0003-1439-1973
Mariona PascalDepartment of Immunology, CDB, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0003-0549-9720
Frank RedegeldDivision of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0001-8830-7960
David RosenstreichDepartment of Internal Medicine/Allergy and Immunology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.ORCID 0000-0003-0612-3450
Franziska Roth-WalterComparative Medicine, The Interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University of Vienna, University of Vienna, Vienna, Austria.ORCID 0000-0001-5005-9228
Carsten Schmidt-WeberCenter of Allergy & Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany.ORCID 0000-0002-3203-8084
Mohamed ShamjiImmunomodulation and Tolerance Group, Imperial College London, and Allergy and Clinical Immunology, Imperial College London, London, United Kingdom.ORCID 0000-0003-3425-3463
Esther H StevelingDepartment of Dermatology, University of Basel, Basel, Switzerland.ORCID 0000-0002-4303-0571
Michelle C TurnerBarcelona Institute for Global Health (ISGlobal), Barcelona, Spain.ORCID 0000-0002-6431-1997
Eva UntersmayrCenter of Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University Vienna, Vienna, Austria.ORCID 0000-0002-1963-499X
Erika Jensen-JarolimComparative Medicine, The Interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University of Vienna, University of Vienna, Vienna, Austria.ORCID 0000-0003-4019-5765
Sophia N KaragiannisSt. John's Institute of Dermatology, School of Basic & Medical Biosciences, Guy's Hospital, King's College London, London, United Kindgom.ORCID 0000-0002-4100-7810
Guy's Hospital · GBUniversity of Veterinary Medicine Vienna · ATAlbert Einstein College of Medicine · USMedical University of Vienna · ATUniversity of Basel · CHBarcelona Institute for Global Health · ESBoston Children's Hospital · USBrigham and Women's Hospital · USCenter for Environmental Health · USHebrew University of Jerusalem · ILHospital Clínic de Barcelona · ESImperial College London · GBInserm · FRKing's College London · GBLuxembourg Institute of Health · LUTransylvania University of Brașov · ROUniversidad San Pablo CEU · ESUPMC Hillman Cancer Center · USUtrecht University · NLWroclaw Medical University · PL
Funding
Medical Research Council MR/L023091/1
6 · The paper itself
Abstract
The immune system interacts with many nominal 'danger' signals, endogenous danger-associated (DAMP), exogenous pathogen (PAMP) and allergen (AAMP)-associated molecular patterns. The immune context under which these are received can promote or prevent immune activating or inflammatory mechanisms and may orchestrate diverse immune responses in allergy and cancer. Each can act either by favouring a respective pathology or by supporting the immune response to confer protective effects, depending on acuity or chronicity. In this Position Paper under the collective term danger signals or DAMPs, PAMPs and AAMPs, we consider their diverse roles in allergy and cancer and the connection between these in AllergoOncology. We focus on their interactions with different immune cells of the innate and adaptive immune system and how these promote immune responses with juxtaposing clinical outcomes in allergy and cancer. While danger signals present potential targets to overcome inflammatory responses in allergy, these may be reconsidered in relation to a history of allergy, chronic inflammation and autoimmunity linked to the risk of developing cancer, and with regard to clinical responses to anti-cancer immune and targeted therapies. Cross-disciplinary insights in AllergoOncology derived from dissecting clinical phenotypes of common danger signal pathways may improve allergy and cancer clinical outcomes.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper. · full record | OpenQuestion